| Literature DB >> 3693906 |
L M Muul1, K Nason-Burchenal, C Hyatt, S Schwarz, D Slavin, E P Director, S A Rosenberg.
Abstract
Lymphokine activated killer (LAK) cells administered in conjunction with recombinant interleukin-2 can mediate the regression of metastatic tumor in some patients with advanced cancer. In these trials LAK cells were activated in medium containing 2% human type A or AB serum. We have found three commercially available, serum-free culture media which allow development of in vitro LAK activity by human peripheral blood lymphocytes. They are AIMV (Gibco), MASF-3 (Whitaker-MA Bioproducts) and HB-104 (Dupont). If 2-mercaptoethanol was added to these culture media they were also capable of generating murine LAK cells which were effective in reducing pulmonary metastases in the murine MCA-106 model. Although LAK cells generated in these media have not been tested in humans yet, potentially they could provide a safe, unlimited and less expensive source of culture fluid for generating the large numbers of LAK cells needed for human clinical trials.Entities:
Mesh:
Substances:
Year: 1987 PMID: 3693906 DOI: 10.1016/0022-1759(87)90265-1
Source DB: PubMed Journal: J Immunol Methods ISSN: 0022-1759 Impact factor: 2.303